Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses

Molecular Psychiatry volume 15, pages 101–112 (2010)Cite this article

Abstract

Marijuana (MJ) is the most commonly used illicit drug in the United States. Its abuse is associated with cognitive dysfunctions and increased resistance to blood flow in the cerebral vasculature. In addition, MJ abuse is associated with increased risks of potentially serious cardiovascular disorders. In the present study, we used the protein chip platform based on surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI-TOF-MS) to test the possibility that MJ abuse might be associated with changes in serum protein levels. Indeed, MJ users showed significant increases in three protein peaks, which were identified as three isoforms of apolipoprotein (apo) C-III. Immunoprecipitation using an apoC-III antibody also validated the identification of the proteins. Marijuana-induced increases in apoC-III levels might occur through chronic stimulation of hepatic cannabinoid receptors (CB1 and/or CB2) by its active ingredient, Δ9tetrahydrocannibol (THC). Thus, chronic MJ abuse might cause increased transcription and/or translation of apoC-III in the liver with corresponding changes reflected in the plasma of these patients. In any case, because apoC-III is a cardiovascular risk factor, the increased levels observed in MJ users might explain, in part, the cardiac and cerebral abnormalities reported in these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. NSDUH Report. Daily Marijuana Users. Survey Report. Rockville, MD: Substance Abuse and Health Services Administration (SAMHSA); 2004.

  2. Fisher BA, Ghuran A, Vadamalai V, Antonios TF . Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005; 22: 679–680.

    Article  CAS  Google Scholar 

  3. Jones RT . Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42: 58S–63S.

    Article  CAS  Google Scholar 

  4. Aronow WS, Cassidy J . Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med 1974; 291: 65–67.

    Article  CAS  Google Scholar 

  5. Renault PF, Schuster CR, Heinrich R, Freeman DX . Marihuana: standardized smoke administration and dose effect curves on heart rate in humans. Science 1971; 174: 589–591.

    Article  CAS  Google Scholar 

  6. Aronow WS, Cassidy J . Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin Pharmacol Ther 1975; 17: 549–554.

    Article  CAS  Google Scholar 

  7. Johns A . Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116–122.

    Article  CAS  Google Scholar 

  8. Cadet JL, Bolla K, Herning RI . Neurological assessments of marijuana users. Methods Mol Med 2006; 123: 255–268.

    PubMed  Google Scholar 

  9. Lundqvist T . Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 2005; 81: 319–330.

    Article  CAS  Google Scholar 

  10. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123–1131.

    Article  Google Scholar 

  11. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J . Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 2000; 19: 1–22.

    Article  CAS  Google Scholar 

  12. Lawson TM, Rees A . Stroke and transient ischaemic attacks in association with substance abuse in a young man. Postgrad Med J 1996; 72: 692–693.

    Article  CAS  Google Scholar 

  13. McCarron MO, Thomas AM . Cannabis and alcohol in stroke. Postgrad Med J 1997; 73: 448.

    Article  CAS  Google Scholar 

  14. Mesec A, Rot U, Grad A . Cerebrovascular disease associated with marijuana abuse: a case report. Cerebrovasc Dis 2001; 11: 284–285.

    Article  CAS  Google Scholar 

  15. Zachariah SB . Stroke after heavy marijuana smoking. Stroke 1991; 22: 406–409.

    Article  CAS  Google Scholar 

  16. Gaoni Y, Mechoulam R . The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93: 217–224.

    Article  CAS  Google Scholar 

  17. Pertwee RG . Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129–180.

    CAS  Google Scholar 

  18. Di Marzo V, Bifulco M, De Petrocellis L . The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771–784.

    Article  CAS  Google Scholar 

  19. Carlson SM, Najmi A, Whitin JC, Cohen HJ . Improving feature detection and analysis of surface-enhanced laser desorption/ionization-time of flight mass spectra. Proteomics 2005; 5: 2778–2788.

    Article  CAS  Google Scholar 

  20. Lin Z, Jenson SD, Lim MS, Elenitoba-Johnson KS . Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod Pathol 2004; 17: 670–678.

    Article  CAS  Google Scholar 

  21. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572–577.

    Article  CAS  Google Scholar 

  22. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835–1843.

    CAS  PubMed  Google Scholar 

  23. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609–3614.

    CAS  PubMed  Google Scholar 

  24. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW . Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296–1304.

    CAS  PubMed  Google Scholar 

  25. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry; e-pub ahead of print: published online 16 October 2007.

  26. Gold MS, Graham NA, Kobeissy FH, Pepine CJ, Goldberger BA . Speed, cocaine, and other psychostimulants death rates. Am J Cardiol 2007; 100: 1184.

    Article  Google Scholar 

  27. McLellan AT, Luborsky L, O’Brien CP, Barr HL, Evans F . Alcohol and drug abuse treatment in three different populations: is there improvement and is it predictable? Am J Drug Alcohol Abuse 1986; 12: 101–120.

    Article  CAS  Google Scholar 

  28. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL . Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337–1343.

    Article  CAS  Google Scholar 

  29. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD . Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096–1103.

    Article  CAS  Google Scholar 

  30. Righetti PG, Castagna A, Antonioli P, Boschetti E . Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 2005; 26: 297–319.

    Article  CAS  Google Scholar 

  31. Le Bihan MC, Tarelli E, Coulton GR . Evaluation of an integrated strategy for proteomic profiling of skeletal muscle. Proteomics 2004; 4: 2739–2753.

    Article  CAS  Google Scholar 

  32. Aryana A, Williams MA . Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 2007; 118: 141–144.

    Article  Google Scholar 

  33. Hospattankar AV, Fairwell T, Meng M, Ronan R, Brewer Jr HB . Identification of sequence homology between human plasma apolipoprotein B-100 and apolipoprotein B-48. J Biol Chem 1986; 261: 9102–9104.

    CAS  PubMed  Google Scholar 

  34. Jong MC, Hofker MH, Havekes LM . Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 472–484.

    Article  CAS  Google Scholar 

  35. Ito Y, Breslow JL, Chait BT . Apolipoprotein C-III0 lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J Lipid Res 1989; 30: 1781–1787.

    CAS  PubMed  Google Scholar 

  36. Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G . Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. J Lipid Res 1981; 22: 800–810.

    CAS  PubMed  Google Scholar 

  37. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78: 1287–1295.

    Article  CAS  Google Scholar 

  38. Kinnunen PK, Ehnolm C . Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 1976; 65: 354–357.

    Article  CAS  Google Scholar 

  39. Weber P, Raederstorff D . Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids—a review. Nutr Metab Cardiovasc Dis 2000; 10: 28–37.

    CAS  PubMed  Google Scholar 

  40. Carlson LA, Ballantyne D . Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia. Atherosclerosis 1976; 23: 563–568.

    Article  CAS  Google Scholar 

  41. Malmendier CL, Delcroix C, Lontie JF . Kinetics of a heterogeneous population of particles in low density lipoprotein apolipoprotein B. Atherosclerosis 1989; 80: 91–100.

    Article  CAS  Google Scholar 

  42. Schonfeld G, George PK, Miller J, Reilly P, Witztum J . Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 1979; 28: 1001–1010.

    Article  CAS  Google Scholar 

  43. Ito Y, Azrolan N, O’Connell A, Walsh A, Breslow JL . Hypertriglyceridemia as a result of human Apo CIII gene expression in transgenic mice. Science 1990; 249: 790–793.

    Article  CAS  Google Scholar 

  44. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J . Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269: 23610–23616.

    CAS  PubMed  Google Scholar 

  45. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM . Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681–687.

    Article  CAS  Google Scholar 

  46. Kalofoutis A, Dionyssiou-Asteriou A, Maravelias C, Koutselinis A . Changes of HDL-lipid composition as related to delta 9-THC action. Pharmacol Biochem Behav 1985; 22: 343–345.

    Article  CAS  Google Scholar 

  47. Panin LE, Shalbueva NI, Polyakov LM . Effects of apolipoproteins C on oxidative phosphorylation in rat liver mitochondria. Bull Exp Biol Med 2000; 130: 769–771.

    Article  CAS  Google Scholar 

  48. Sarafian TA, Habib N, Oldham M, Seeram N, Lee RP, Lin L et al. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1202–L1209.

    Article  CAS  Google Scholar 

  49. Ponto LL, O’Leary DS, Koeppel J, Block RI, Watkins GL, Richmond JC et al. Effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O] water: effect in occasional and chronic users. J Clin Pharmacol 2004; 44: 751–766.

    Article  CAS  Google Scholar 

  50. Benowitz NL, Jones RT . Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 1981; 21: 214S–223S.

    Article  CAS  Google Scholar 

  51. Beaconsfield P, Ginsburg J, Rainsbury R . Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 1972; 287: 209–212.

    Article  CAS  Google Scholar 

  52. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.

    Article  CAS  Google Scholar 

  53. Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.

    Article  CAS  Google Scholar 

  54. Adams IB, Martin BR . Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585–1614.

    Article  CAS  Google Scholar 

  55. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298–1305.

    Article  CAS  Google Scholar 

  56. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90: 1434–1439.

    Article  CAS  Google Scholar 

  57. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW . Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 2002; 127: 169–176.

    Article  CAS  Google Scholar 

  58. Zannis VI, Kan HY, Kritis A, Zanni E, Kardassis D . Transcriptional regulation of the human apolipoprotein genes. Front Biosci 2001; 6: D456–D504.

    Article  CAS  Google Scholar 

  59. Gruber PJ, Torres-Rosado A, Wolak ML, Leff T . Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element. Nucleic Acids Res 1994; 22: 2417–2422.

    Article  CAS  Google Scholar 

  60. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS . Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004; 173: 2373–2382.

    Article  CAS  Google Scholar 

  61. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C . Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989; 125: 267–274.

    Article  CAS  Google Scholar 

  62. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882–888.

    Article  CAS  Google Scholar 

  63. Lee SJ, Campos H, Moye LA, Sacks FM . LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23: 853–858.

    Article  CAS  Google Scholar 

  64. Herning RI, Better WE, Tate K, Cadet JL . Marijuana abusers are at increased risk for stroke. Preliminary evidence from cerebrovascular perfusion data. Ann N Y Acad Sci 2001; 939: 413–415.

    Article  CAS  Google Scholar 

  65. Herning RI, Better W, Tate K, Cadet JL . EEG deficits in chronic marijuana abusers during monitored abstinence: preliminary findings. Ann N Y Acad Sci 2003; 993: 75–78; discussion 79–81.

    Article  Google Scholar 

  66. Poirier J . Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003; 9: 94–101.

    Article  CAS  Google Scholar 

  67. Hirsch-Reinshagen V, Wellington CL . Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol 2007; 18: 325–332.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by the Intramural Research Program of the NIH, NIDA.

Author information

Authors and Affiliations

  1. Molecular Neuropsychiatry Branch, NIH, BRC, Baltimore, MD, USA

    S Jayanthi, S Buie, R I Herning, W Better, N M Wilson & J L Cadet

  2. Ciphergen Biosystems, Freemont, CA, USA

    S Moore

  3. Office of the Clinical Director, National Institute on Drug Abuse-Intramural Research Program, NIH, BRC, Baltimore, MD, USA

    C Contoreggi

Authors
  1. S Jayanthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Buie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R I Herning
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Better
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N M Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Contoreggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L Cadet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J L Cadet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jayanthi, S., Buie, S., Moore, S. et al. Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses. Mol Psychiatry 15, 101–112 (2010). https://doi.org/10.1038/mp.2008.50

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2008.50

Keywords

This article is cited by

Search

Advanced search

Quick links